{"entity":{"id":"cryptophycin-payloads","kind":"term","name":"Cryptophycin payloads","aka":["cryptophycin-55","cryptophycin-52","aza-cryptophycin payloads"],"tldr":"Cryptophycin payloads are powerful blockers of cell division. Antibody-linked versions are being investigated to improve how these drugs reach tumors.","summary":"Cryptophycin-55 derivatives have been attached to trastuzumab and tested in HER2-positive cell lines and mouse xenografts. Cryptophycin-52 is a tubulin inhibitor; the primary conjugate study investigated release and conversion of the cryptophycin-55 prodrug. This is an experimental tubulin-directed scaffold. Activity of the free molecule, prodrug and intact antibody conjugate must be distinguished.","asOf":"2026-11-08","links":[{"label":"Lai et al., cryptophycin-55/52 antibody conjugates (2020)","url":"https://doi.org/10.1016/j.ejmech.2020.112364"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload","tubulin-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/cryptophycin-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/"}]}}